benfotiamine造句

• Benfotiamine blocked all three damage pathways by converting the damaging compounds into harmless chemicals.
• It is thought that treatment with benfotiamine leads to increased intracellular thiamine diphosphate levels,
• While benfotiamine is a synthetic derivative of thiamine, it is different from that vitamin, Brownlee said.
• Therefore additional clinical studies are mandatory to explore the therapeutic potential of benfotiamine in both diabetic and non-diabetic pathological conditions ".
• Benfotiamine is an oral prodrug of Vitamin B1 that has several placebo-controlled double-blind trials proving efficacy in treating neuropathy and various other diabetic comorbidities.
• German researchers on the team suggested trying the synthetic thiamine form, benfotiamine, and it increased the enzyme activity by 300 percent to 400 percent, Brownlee said.
• Benfotiamine may be useful for the treatment of diabetic retinopathy, neuropathy, and nephropathy however " Most of the effects attributed to benfotiamine are extrapolated from in vitro and animal studies.
• Benfotiamine may be useful for the treatment of diabetic retinopathy, neuropathy, and nephropathy however " Most of the effects attributed to benfotiamine are extrapolated from in vitro and animal studies.
• In addition, benfotiamine has been in use in Germany for years to treat painful types of nerve damage, including nerve damage caused by diabetes, and seems to have few side effects.
• In more severe cases of nutritional deficiency 320 mg / day of benfotiamine for 4 weeks followed by 120 mg / day for 4 more weeks may be prescribed in an effort to return thiamine levels to normal.
• Compounds that have been found to inhibit AGE formation in the laboratory include Vitamin C, benfotiamine, pyridoxamine, alpha-lipoic acid, taurine, pimagedine, aspirin, carnosine, metformin, pioglitazone, and pentoxifylline.
• Diabetic rats treated with benfotiamine for 36 weeks did not develop any of the retina damage found in a similar group of untreated rats, according to a research team led by Dr . Michael Brownlee of the Albert Einstein College of Medicine in New York.